文献速递乳腺癌

病理-基因组联合算法优化早期乳腺癌21基因复发评分检测的成本效益

Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
PubMed 文献 · Ann Oncol · 2018-01-01

本研究基于2005年至2015年前瞻性收集的1268例接受21基因复发评分(RS)检测的浸润性乳腺癌病例,比较Anne Arundel医学中心(AAMC)模型与RS风险分组在5年远处复发率(DRR)上的一致性,并评估病理-基因组(P-G)算法(仅对AAMC中危患者行RS检测)的预后判别能力与避免RS检测的比例。结果显示AAMC低危与RS低危、AAMC高危与RS高危的5年DRR相似,P-G算法可扩大低危和高危分组且预后准确性相当,并使44%的患者避免RS检测。

要点

  • AAMC模型预测的5年远处复发率与21基因RS风险分组相似。
  • P-G算法仅对AAMC中危患者行RS检测,44%的患者可避免RS检测。
  • P-G算法可扩大低危和高危分组,且预后准确性相似。

核心结论

  • AAMC模型能够类似RS地区分高危和低危组的5年复发。
  • 采用P-G算法将RS检测保留给AAMC中危病例,可扩大低危和高危组且预后准确性相似。
  • P-G算法可靠识别出相当一部分不可能从RS检测中获益的患者,并改善风险分类能力。

研究设计与样本

  • 研究为生存分析,使用前瞻性收集的机构数据库。
  • 纳入2005年2月至2015年5月新诊断并接受RS检测的浸润性乳腺癌病例,共1268例。
  • 根据AAMC模型将患者分配至风险类别,采用Kaplan-Meier法评估5年远处复发率(DRR)。

主要发现

  • AAMC低危组5年DRR为2.7%(n=322),RS<18低危组为3.4%(n=703)。
  • AAMC高危组5年DRR为22.8%(n=230),RS>30高危组为23.0%(n=141)。
  • 采用P-G算法,低危组5年DRR为3.3%(n=739),高危组为24.2%(n=272)。
  • 采用P-G算法,44%(552/1268)的患者可避免RS检测。

临床怎么用

  • 对于激素受体阳性、淋巴结阴性的早期乳腺癌,可考虑使用AAMC模型预测RS风险类别。
  • 采用P-G算法,仅对AAMC中危患者进行RS检测,可避免部分患者接受RS检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 21-gene recurrence score (RS) (Oncotype DX®; Genomic Health, Redwood City, CA) partitions hormone receptor positive, node negative breast cancers into three risk groups for recurrence. The Anne Arundel Medical Center (AAMC) model has previously been shown to accurately predict RS risk categories using standard pathology data. A pathologic-genomic (P-G) algorithm then is presented using the AAMC model and reserving the RS assay only for AAMC intermediate-risk patients. PATIENTS AND METHODS: A survival analysis was done using a prospectively collected institutional database of newly diagnosed invasive breast cancers that underwent RS assay testing from February 2005 to May 2015. Patients were assigned to risk categories based on the AAMC model. Using Kaplan-Meier methods, 5-year distant recurrence rates (DRR) were evaluated within each risk group and compared between AAMC and RS-defined risk groups. Five-year DRR were calculated for the P-G algorithm and compared with DRR for RS risk groups and the AAMC model's risk groups. RESULTS: A total of 1268 cases were included. Five-year DRR were similar between the AAMC low-risk group (2.7%, n = 322) and the RS < 18 low-risk group (3.4%, n = 703), as well as between the AAMC high-risk group (22.8%, n = 230) and the RS > 30 high-risk group (23.0%, n = 141). Using the P-G algorithm, more patients were categorized as either low or high risk and the distant metastasis rate was 3.3% for the low-risk group (n = 739) and 24.2% for the high-risk group (n = 272). Using the P-G algorithm, 44% (552/1268) of patients would have avoided RS testing. CONCLUSIONS: AAMC model is capable of predicting 5-year recurrences in high- and low-risk groups similar to RS. Further, using the P-G algorithm, reserving RS for AAMC intermediate cases, results in larger low- and high-risk groups with similar prognostic accuracy. Thus, the P-G algorithm reliably identifies a significant portion of patients unlikely to benefit from RS assay and with improved ability to categorize risk.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gage MM, Mylander WC, Rosman M, et al. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay. Ann Oncol. 2018. PMID: 29788166. doi:10.1093/annonc/mdy074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。